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ABSTRACT: Molecules that disrupt protein aggregation repre-
sent potential tool compounds for the investigation of numerous
human disease states. However, the identification of small
molecules capable of disrupting protein aggregation has proven
challenging. Larger biomolecules such as antibodies and proteins
are promising alternatives due to their increased size. Despite the
promise of protein-based inhibitors, generalizable assays are
needed to more readily identify proteins capable of inhibiting
aggregation. Herein, we utilize our previously reported self-
assembling NanoLuc luciferase fragments to engineer a platform
in which both detection reagents are expressed from the same
plasmid, enabling facile co-transformation with a genetically encodable inhibitor. This streamlined system is capable of detecting
changes in the solubility of amylin, huntingtin, and amyloid-β (Aβ) proteins in response to mutations, small-molecule inhibitors, and
expression of genetically encodable inhibitors. This improved platform provides a means to begin to identify protein-based inhibitors
with improved efficacy.
■ INTRODUCTION
Protein aggregation and the formation of insoluble protein
fibrils are associated with numerous human diseases.1,2 This
has motivated several efforts to identify small-molecule
inhibitors of protein aggregation.3 Although powerful tools,
small-molecule inhibitors suffer from relatively limited surface
areas, hindering their ability to disrupt protein−protein
interactions. Alternatively, protein-based inhibitors provide
the potential to disrupt interactions involving large surface
areas.2−5 However, a lack of assays capable of identifying
protein-based inhibitors of aggregation that function in cellular
environments has limited progress in this area.
Early strategies for the detection of protein aggregates relied
on staining with small molecules, such as thioflavin T and
congo red, capable of producing a change in optical signal in
the presence of aggregates.6−9 These small-molecule probes
remain powerful tools to analyze protein aggregation in vitro
but have limited utility in cellular applications and can produce
false positives when screening for inhibitors of fibrillization.10
To address this issue, genetically encodable reporters of
protein aggregation have been developed.11−15 These reporters
generally rely on using the aggregation of an appended protein-
of-interest to modulate the function of a reporter (Figure 1a).
In an elegant example, a GFP-based folding reporter has been
used to identify small-molecule inhibitors of Aβ aggrega-
tion.16−18 As a complementary approach to monitor protein
aggregation, we have utilized self-assembling fragments of
NanoLuc luciferase (Nluc).19−22 Nluc is a small (19 kDa),
engineered luciferase23,24 and provides a robust platform for
engineering luminescence reporter assays.25,26 We have
previously identified Nluc fragments termed N65 (residues
1−65) and 66C (residues 66−171) that are capable of
spontaneous reassembly to afford functional enzyme.20 Fusion
of a protein-of-interest (POI) to the N-terminus of N65 results
in a change in the amount of N65 available for reassembly that
is proportional to the solubility of the POI. Using this
approach, relative changes in the solubility of the POI as a
result of point mutants or treatment with small-molecule
inhibitors can be assessed (Figure 1b). Our previous platform
relied on the coexpression of POI-N65 and 66C reporter
constructs from different plasmids, complicating the identi-
fication of genetically encodable inhibitors. Herein, we re-
engineer this system using a single plasmid to drive expression
of both reporter components (Figure 1c). This re-engineered
system is used to monitor the solubility of amylin, huntingtin,
and Aβ proteins and is capable of reporting on the relative
influence of mutations, small-molecule inhibitors, and protein-
based inhibitors on aggregation.
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■ RESULTS AND DISCUSSION
In order to investigate the ability to identify protein-based
inhibitors of aggregation, we first examined whether coex-
pression of our reporter system from the same plasmid was
feasible. For this purpose, we chose the commercially available
pETDuet-1 vector, which is compatible with P15A, Mini-F/
RK2, CloDF13, RSF1030, or ColA replicons. We examined
whether mutations known to increase the solubility of amylin
could be detected in this new system. Importantly, we have
previously shown that our split-Nluc fragments are capable of
reporting on the relative increase in the solubility of the I26P
mutant of amylin27 when expressed from separate plasmids.21
Accordingly, wild-type (wt) amylin or the I26P mutant were
fused to the N-terminus of N65 in the 5′ multiple cloning site
of pETDuet-1 (Table S1). The 66C Nluc fragment was cloned
into the 3′ multiple cloning site of pETDuet-1 (Table S1).
These coexpression constructs were transformed into bacteria,
expression was induced by addition of IPTG, and samples were
normalized to cell density prior to luminescence analysis in
intact cells. The I26P mutant showed an increase of 2.3-fold in
the luminescence signal, similar to our lab’s previously
reported results using separate expression plasmids (Figure
2).21 This result suggests that our re-engineered, single-plasmid
system retains the ability to detect changes in protein
solubility.
Building upon this observation, we next asked whether this
system could detect the influence of small-molecule inhibitors
of protein aggregation. Our lab has previously used the split-
Nluc reporters21 to validate the inhibition of amylin
aggregation by silibinin28 as well as the inhibition of huntingtin
protein (Htt) aggregation by cystamine.29−31 To investigate
the ability of our re-engineered platform to report on changes
in Htt solubility, we fused a mutant of Htt containing 97
glutamine repeats (Htt97Q) to the N-terminus of N65.32−34
When expression was induced with IPTG and samples were
normalized for cell densities, we observed an increase in
luminescence in cells incubated with their respective inhibitors
that was consistent with our previously reported data using two
reporter plasmids (Figure 3).21 These experiments indicate
that our re-engineered coexpression platform can be utilized to
identify small-molecule inhibitors of protein aggregation.
Encouraged by these results, we sought to determine
whether the re-engineered platform was also capable of
assessing the influence of genetically encodable inhibitors on
protein aggregation. As a proof-of-concept system, we chose
the evolved miniprotein known as TJ10 (Table S1).35 TJ10 is a
variant of the hyperthermophilic mutant of the IgG-binding
protein (HTB1)36 that was evolved via phage display to bind
to Aβ oligomers and disrupt aggregation in vitro. We have
Figure 1. Cell-based assay systems for detecting protein solubility. (a)
A reporter capable of producing an observable signal is fused to the C-
terminus of a protein-of-interest (POI). The activity of the reporter
protein is modulated by the equilibrium between the folded and
unfolded states. (b) A POI is fused to the N-terminus of N65 (blue).
The equilibrium between folded and unfolded protein dictates the
amount of N65 available for reassembly with 66C (red). Reassembled
N65/66C produces a luminescent signal that is proportional to the
amount of soluble POI. (c) The previously described split-Nluc assay
system was based on two expression plasmids for POI-N65 and
66C.20 The re-engineered split-Nluc assay system utilizes a single
plasmid to drive the expression of both POI-N65 and 66C proteins,
allowing for the interrogation of genetically encodable inhibitors.
Figure 2. Monitoring the influence of mutations on amylin solubility
using the single-plasmid split-Nluc assay. (a) The amino acid
sequence of amylin is shown with the mutation site indicated in
red. (b) A dramatic increase in the luminescence of bacterial cells
expressing the I26P mutant is observed relative to cells expressing
wild-type (wt) protein using the Nano-Glo Live Cell Assay reagent.
Error bars represent the standard deviation of three biological
replicates assayed in triplicate. *** indicates a p-value of <0.001.
Figure 3. Monitoring the influence of small molecules on protein
solubility using the single-plasmid split-Nluc assay. (a) The structure
of silibinin, a known inhibitor of amylin aggregation, is shown. (b)
Luminescence from bacterial cells expressing amylin-N65/66C in the
presence or absence of silibinin using coelenterazine as the substrate.
(c) The structure of cystamine, a known inhibitor of Htt aggregation,
is shown. (d) Luminescence from bacterial cells expressing
Htt97QN65/66C in the presence or absence of cystamine using
coelenterazine as the substrate. Error bars represent the standard
deviation of three biological replicates assayed in triplicate. **
indicates a p-value of <0.01 and *** indicates a p-value of <0.001.
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previously reported the ability of the split-Nluc assay system to
detect changes in Aβ1−42 aggregation upon treatment of lysates
with o-vanillin.20 However, this small-molecule inhibitor was
found to be toxic to living cells at the concentrations required
for inhibition of Aβ1−42 aggregation. In the long term, we
hypothesize that our re-engineered system may allow for the
identification of protein-based inhibitors of Aβ1−42 aggregation
with reduced toxicity. Toward this goal, Aβ1−42 was fused to
the N-terminus of N65 in the dual-expression vector and TJ10
was subsequently cloned into the 5′ cloning site of a
complementary expression vector, pRSFDuet-1, containing a
RSF1030 replicon (Table S1). We hypothesized that the use of
a higher-copy plasmid as well as a T7 promoter for the
genetically encodable inhibitor would saturate the split-Nluc
reporter system, potentially enabling identification of weak
inhibitors in future experiments. Bacteria were then either
transformed with the Aβ1−42-N65/66C dual-expression system
alone or co-transformed with the plasmid expressing TJ10.
Bacterial cultures were induced with IPTG, normalized for cell
density, and intact cells were assayed for changes in
luminescence. We observed a significant 90% increase in
luminescence when TJ10 was co-expressed with the Aβ1−42-
N65/66C detection system (Figure 4). Given the higher copy
number of the pRSFDuet-1 plasmid, we investigated whether
TJ10 was present at saturating concentrations within cells. This
was confirmed by cloning a second copy of TJ10 into the 3′
site of pRSFDuet-1, the resulting dual-TJ10 expression vector
yielded a similar luminescence increase to the single-copy
plasmid (Figure S1). Interestingly, expression of TJ10 in the
amylin and Htt97Q reporter systems resulted in 20 and 46%
increases in luminescence, respectively (Figure S2). This may
indicate that TJ10 recognizes common oligomeric structures
shared by these proteins and Aβ1−42, similar to previously
described oligomer-specific antibodies.37 Taken together, these
experiments demonstrate that our re-engineered assay platform
can be utilized for the straightforward interrogation of
genetically encoded inhibitors of protein aggregation.
■ CONCLUSIONS
We have re-engineered a split-Nluc platform to utilize a single
coexpression plasmid to drive production of the detection
constructs. This platform is capable of detecting changes in
protein solubility resulting from mutations as well as addition
of small molecules. The assay retained its functionality for
detecting amylin, huntingtin, and Aβ protein aggregation.
Building upon the ease of co-transformation in this system, we
demonstrated the ability to interrogate the influence of
genetically encodable inhibitors on protein aggregation.
Previous work has demonstrated that the split-Nluc system is
capable of producing a >10-fold change in luminescent signal
depending on the solubility of the protein fused to N65,20 thus
we expect that the systems described herein can be used
directly for identification of inhibitors. Efforts to further
improve the dynamic range of the assay are focused on
increasing the reassembly efficiency of N65 and 66C, which is
currently ∼0.1%.20 Given the ability to generate DNA libraries
of mutant proteins and peptides,38−41 we anticipate that these
new assay systems could potentially be used in their current
form to identify protein-based inhibitors of protein aggrega-
tion.
■ METHODS
Small-Molecule Inhibitor Stocks. Silibinin (amylin
aggregation inhibitor) was prepared as a 200× stock solution
at a concentration of 1 mM in dimethyl sulfoxide (DMSO).
Cystamine (Htt aggregation inhibitor) was prepared as a
1000× stock solution at 50 mM in water.
Cloning of N65 Fusions and 66C into pETDuet-1.
Sequences for Aβ1−42-N65, amylin-N65, Htt97Q-N65, and
66C were amplified from previously described vectors.20,21
DNA sequences encoding for N-terminal fusions to N65 were
cloned into the first multiple cloning site of the pETDuet-1
vector (Novagen, TB337) using primers containing 5′ NcoI
and 3′ NotI restriction sites. The DNA sequence correspond-
ing to the C-terminal Nluc fragment (residues 66−171) was
then incorporated into the second multiple cloning site using
primers containing 5′ NdeI and 3′ XhoI restriction sites.
Ligated DNA was transformed into XL1-Blue competent cells
(Agilent, #200249) and amplified on LB plates containing
ampicillin (100 μg/mL). The amylin I26P mutant was
generated using site-directed mutagenesis according to the
manufacture’s protocol (QuikChange XL Site-Directed Muta-
genesis Kit, Agilent, #200517). Plasmids were verified by DNA
sequencing.
Cloning of TJ10 into pRSFDuet-1. A DNA sequence
encoding for TJ1035 was cloned into the first multiple cloning
site of the pRSFDuet-1 vector (Novagen, TB391) using
primers containing 5′ BamHI and 3′ NotI restriction sites.
Where indicated, a second copy of TJ10 was cloned into the
second multiple cloning site of the vector using primers
containing 5′ NdeI and 3′ KpnI restriction sites. Ligated DNA
was transformed into XL1-Blue competent cells and amplified
on LB plates containing kanamycin (50 μg/mL). Plasmids
were verified by DNA sequencing.
Solubility Assays. Samples were prepared according to
previous procedures.19 Briefly, BL21-Gold(DE3) cells (Agi-
lent, #230132) were transformed with the indicated construct/
s and grown overnight in terrific broth (TB, 5 mL) with
shaking at 37 °C in the presence of the appropriate antibiotics
(ampicillin at 100 μg/mL and kanamycin at 50 μg/mL). The
Figure 4. Monitoring inhibition of Aβ1−42 aggregation in bacterial
cells using a genetically encodable inhibitor. (a) The amino acid
sequence of the first two β-strands of TJ10 with the residues selected
for binding to Aβ shown in blue. (b) A structural model of TJ10
(based on HTB1, PDB: 1GB4) with the positions of the mutated
residues shown in blue. (c) A clear increase in the luminescence of
cells expressing TJ10 is observed using furimazine as the substrate.
Error bars represent the standard deviation of three biological
replicates assayed in triplicate. * indicates a p-value of <0.05.
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optical density of each sample was measured at 600 nm, and
samples were diluted to an OD600 = 0.1 in 5 mL. The cells
were grown in a shaker at 37 °C until they reached an OD600 =
0.6−0.8 and were then induced with IPTG (0.2 mM final
concentration). Small-molecule inhibitors were then added as
indicated. The cells were subsequently incubated overnight,
with shaking at 16 °C. The next morning, the OD600 of the
sample was measured and each culture was normalized to an
OD600 = 3.0 in 1 mL of TB, except in Figure 2b where each
culture was normalized to an OD600 = 0.003 in 1 mL of TB due
to the use of the more-sensitive Nano-Glo Live Cell Assay
reagent (see below). Cells were then harvested by
centrifugation at 700g for 10 min at 4 °C and resuspended
in 200 μL of 1× Nluc assay buffer (50 mM 2-ethanesulfonic
acid (MES) pH = 6.0, 0.5 mM ethylenediaminetetraacetic acid
(EDTA), 75 mM KCl, 1 mM 2-mercaptoethanol, and 17.5
mM thiourea) or 200 μL of nanopure water when using the
Nano-Glo Live Cell Assay reagent. The cells were then mixed
with either 200 μL of Nano-Glo Live Cell Assay reagent
(Promega, N2011) prepared according to the manufacture’s
protocol or 200 μL of 1× Nluc assay buffer containing either
furimazine (Promega, N1110, 2% v/v) or coelenterazine
(GoldBio, CZ2.5, 25 μM final concentration) as indicated.
Relative changes in luminescence obtained in assays using
either furimazine or coelenterazine are comparable.20 The
resulting mixtures were then loaded into a 384-well assay plate
(Corning, 3824, white, low volume, flat bottom, 40 μL sample
volume per well). Luminescence intensities were measured 30
min after addition of the substrate using a SynergyH1 hybrid
reader (BioTek). Relative luminescence data are shown and
represent the average of triplicate experiments conducted on
three biological replicates. Error is reported as the standard
deviation. Reported p-values were calculated using a two-tailed,
unpaired t-test.
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